1[2]Nelson HS, Berkowitz RB, Tinkelman DA, et al. Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med, 1999,159:1556 被引量：1
2[3]Woolcock JC, Saarelainen PAJ, Lundback B, et al. Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. Respir Med,2000,94(7):715 被引量：1
3[4]Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized controlled trial. Ann Int Med,1999,130:487 被引量：1
4[5]Williams J. Efficacy and ease of use of the fluticasone propionate multi-dose powder inhaler compared with budesonide reservoir powder device in asthmatic children. Eur Respir J ,1995, 8(suppl19):469s 被引量：1
5[6]Wilson AM, Mcfarlane LC, Lipworth BJ . Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med, 1997,156(4):1274 被引量：1
6[7]Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol, 2000, 106(3 Pt1):485 被引量：1
7[8]Parameswaran KN, Inman MD, Ekholm BP, et al.Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta 2-agonist. Am J Respir Crit Care Med, 1999,160:354 被引量：1
8[1]Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet,1995,346:201 被引量：1
3Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for thediagnosis, management, and prevention of chronic obstructivepulmonary disease: gold executive summary[J]. Am J Respir CritCare Med, 2013,187(4): 347-365. 被引量：1
